Drug Profile
Research programme: RNA-targeted small molecule therapeutics - Celgene/Skyhawk Therapeutics
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Celgene Corporation; Skyhawk Therapeutics
- Developer Skyhawk Therapeutics
- Class Anti-inflammatories; Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Neurological disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Inflammation in USA
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in USA
- 28 Feb 2022 No recent reports of development identified for research development in Neurological-disorders in USA